Preoperative evaluation of pancreatic adenocarcinoma

Colin M. Parsons, Julie Sutcliffe, Richard J Bold

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The preoperative evaluation of resectability for pancreatic cancer fails to identify up to 25% of patients who are unfortunately found to be unresectable at surgical exploration. Inoperative findings in this circumstance is usually due to either small volume metastatic disease or regional tumor invasion. While advances in computed tomography (CT) technology has increased accuracy of local tumor extent, occult metastatic disease remains a common problem. Although 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been demonstrated to be useful in the staging of many malignancies (e.g. esophageal cancer, recurrent colorectal cancer, lung cancer), it has not been found to significantly increase the accuracy of determining resectability preoperatively in pancreatic cancer, especially with regard to detection of small volume metastatic disease. There are a variety of pancreatic cancer-specific antigens which are being developed as a method for targeted molecular imaging; we provide preliminary data targeting the integrin αvβ6 to demonstrate the potential feasibility of this approach. Further developments may allow the accurate determination of patients with resectable pancreatic cancer, and more importantly, those with unresectable disease that may forego unnecessary surgery, the associated morbidity, and the subsequent delay of appropriate therapy.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalJournal of Hepato-Biliary-Pancreatic Surgery
Volume15
Issue number4
DOIs
StatePublished - 2008

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Lung Neoplasms
Unnecessary Procedures
Neoplasms
Molecular Imaging
Fluorodeoxyglucose F18
Esophageal Neoplasms
Integrins
Positron-Emission Tomography
Colorectal Neoplasms
Tomography
Technology
Morbidity
Antigens
Therapeutics

Keywords

  • Pancreatic cancer
  • PET scan
  • Preoperative imaging
  • Tumor markers

ASJC Scopus subject areas

  • Surgery

Cite this

Preoperative evaluation of pancreatic adenocarcinoma. / Parsons, Colin M.; Sutcliffe, Julie; Bold, Richard J.

In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 15, No. 4, 2008, p. 429-435.

Research output: Contribution to journalArticle

@article{5c6d97872c8441e7b28bf69969287778,
title = "Preoperative evaluation of pancreatic adenocarcinoma",
abstract = "The preoperative evaluation of resectability for pancreatic cancer fails to identify up to 25{\%} of patients who are unfortunately found to be unresectable at surgical exploration. Inoperative findings in this circumstance is usually due to either small volume metastatic disease or regional tumor invasion. While advances in computed tomography (CT) technology has increased accuracy of local tumor extent, occult metastatic disease remains a common problem. Although 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been demonstrated to be useful in the staging of many malignancies (e.g. esophageal cancer, recurrent colorectal cancer, lung cancer), it has not been found to significantly increase the accuracy of determining resectability preoperatively in pancreatic cancer, especially with regard to detection of small volume metastatic disease. There are a variety of pancreatic cancer-specific antigens which are being developed as a method for targeted molecular imaging; we provide preliminary data targeting the integrin αvβ6 to demonstrate the potential feasibility of this approach. Further developments may allow the accurate determination of patients with resectable pancreatic cancer, and more importantly, those with unresectable disease that may forego unnecessary surgery, the associated morbidity, and the subsequent delay of appropriate therapy.",
keywords = "Pancreatic cancer, PET scan, Preoperative imaging, Tumor markers",
author = "Parsons, {Colin M.} and Julie Sutcliffe and Bold, {Richard J}",
year = "2008",
doi = "10.1007/s00534-007-1240-7",
language = "English (US)",
volume = "15",
pages = "429--435",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Preoperative evaluation of pancreatic adenocarcinoma

AU - Parsons, Colin M.

AU - Sutcliffe, Julie

AU - Bold, Richard J

PY - 2008

Y1 - 2008

N2 - The preoperative evaluation of resectability for pancreatic cancer fails to identify up to 25% of patients who are unfortunately found to be unresectable at surgical exploration. Inoperative findings in this circumstance is usually due to either small volume metastatic disease or regional tumor invasion. While advances in computed tomography (CT) technology has increased accuracy of local tumor extent, occult metastatic disease remains a common problem. Although 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been demonstrated to be useful in the staging of many malignancies (e.g. esophageal cancer, recurrent colorectal cancer, lung cancer), it has not been found to significantly increase the accuracy of determining resectability preoperatively in pancreatic cancer, especially with regard to detection of small volume metastatic disease. There are a variety of pancreatic cancer-specific antigens which are being developed as a method for targeted molecular imaging; we provide preliminary data targeting the integrin αvβ6 to demonstrate the potential feasibility of this approach. Further developments may allow the accurate determination of patients with resectable pancreatic cancer, and more importantly, those with unresectable disease that may forego unnecessary surgery, the associated morbidity, and the subsequent delay of appropriate therapy.

AB - The preoperative evaluation of resectability for pancreatic cancer fails to identify up to 25% of patients who are unfortunately found to be unresectable at surgical exploration. Inoperative findings in this circumstance is usually due to either small volume metastatic disease or regional tumor invasion. While advances in computed tomography (CT) technology has increased accuracy of local tumor extent, occult metastatic disease remains a common problem. Although 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been demonstrated to be useful in the staging of many malignancies (e.g. esophageal cancer, recurrent colorectal cancer, lung cancer), it has not been found to significantly increase the accuracy of determining resectability preoperatively in pancreatic cancer, especially with regard to detection of small volume metastatic disease. There are a variety of pancreatic cancer-specific antigens which are being developed as a method for targeted molecular imaging; we provide preliminary data targeting the integrin αvβ6 to demonstrate the potential feasibility of this approach. Further developments may allow the accurate determination of patients with resectable pancreatic cancer, and more importantly, those with unresectable disease that may forego unnecessary surgery, the associated morbidity, and the subsequent delay of appropriate therapy.

KW - Pancreatic cancer

KW - PET scan

KW - Preoperative imaging

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=48749093921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749093921&partnerID=8YFLogxK

U2 - 10.1007/s00534-007-1240-7

DO - 10.1007/s00534-007-1240-7

M3 - Article

VL - 15

SP - 429

EP - 435

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 4

ER -